Group 1 - Bid Pharma announced a shareholder reduction plan due to liquidity needs, with shareholders Zhoushan Xinxie, Ningbo Landan, and Mr. Wu Bo planning to reduce their holdings within three months after the announcement [1] - Zhoushan Xinxie and Ningbo Landan plan to reduce up to approximately 908,800 shares each, representing no more than 1% of the total share capital, while Mr. Wu Bo plans to reduce up to approximately 785,800 shares, representing no more than 0.86% of the total share capital [1] - The reduction price will be determined based on the market price at the time of the reduction [1] Group 2 - As of the report, Bid Pharma's market capitalization is 5.9 billion [2]

AI基金兴业医疗保健A（011466）披露2025年半年报，上半年基金利润2581.62万元，加权平均基金份额本期利润0.0707元。报告期内，基金净值增长率为 11.02%，截至上半年末，基金规模为2.49亿元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至9月3日，单位净值为0.89元。基金经理是陈旭。 基金管理人在半年报中表示，对于下半年的医药行业，我们保持审慎乐观，一方面创新药的产业趋势仍将延续，下半年仍会有一系列的海外大额BD交易发 生，整个国内创新药资产仍面临全球化下的估值重塑；另一方面国内诊疗环境经过反腐环境下长周期调整，行业处在逐步改善的阶段。配置上，我们坚持以 产业趋势为视角，做个股的均衡投资。 截至9月3日，兴业医疗保健A近三个月复权单位净值增长率为24.05%，位于同类可比基金68/138；近半年复权单位净值增长率为35.62%，位于同类可比基金 82/138；近一年复权单位净值增长率为44.61%，位于同类可比基金97/136；近三年复权单位净值增长率为23.96%，位于同类可比基金45/108。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为 ...

Group 1 - The core point of the article is that Bid Pharma (688073) announced a plan for its shareholders to reduce their stake in the company by up to 2.86% of the total share capital within three months through various trading methods [1] Group 2 - The shareholders involved in the reduction are Zhoushan Xinxie Enterprise Management Partnership and its concerted parties, Ningbo Landan Enterprise Management Partnership and Wu Bo [1] - The total number of shares to be reduced is up to 2.6035 million shares [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by its shareholders due to personal liquidity needs, which may impact the stock price and market perception of the company [1] Shareholder Reduction Plan - Shareholder Zhoushan Xinxie plans to reduce up to 908,829 shares through block trading, representing 1.00% of the total share capital [1] - Shareholder Ningbo Landan also intends to reduce up to 908,829 shares through block trading, equivalent to 1.00% of the total share capital [1] - Shareholder Wu Bo aims to reduce up to 785,804 shares through centralized bidding, accounting for 0.86% of the total share capital [1] - The reduction prices will be determined based on the market prices at the time of execution [1]

证券代码：688073 证券简称：毕得医药 公告编号：2025-077 上海毕得医药科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 截至本公告披露日，上海毕得医药科技股份有限公司（以下简称"毕得医药" 或"公司"）股东舟山欣曦企业管理合伙企业（有限合伙）（以下简称"舟山欣曦"） 持有公司无限售条件流通股 5,019,806 股，占公司股份总数的 5.52%。股东宁波 兰旦企业管理合伙企业（有限合伙）（以下简称"宁波兰旦"）持有公司股份 4,305,076 股，占公司股份总数的 4.74%，其中 69,486 股为有限售条件流通股， 4,235,590 股为无限售条件流通股。股东吴波持有公司无限售条件流通股 785,804 股，占公司股份总数的 0.86%。舟山欣曦、宁波兰旦、吴波系一致行动人，合计 持有毕得医药 11.12%的股份。 1 总股本的 1.00%；股东吴波拟通过集中竞价交易方式减持公司股份数量不超过 785,804 股，即 ...

智通财经APP讯，毕得医药(688073.SH)公告，公司股东舟山欣曦、宁波兰旦及其一致行动人吴波先生 计划减持其所持有的公司股份。其中，舟山欣曦拟通过大宗交易方式减持公司股份数量不超过90.88万 股，即不超过公司总股本的1.00%;宁波兰旦拟通过大宗交易方式减持公司股份数量不超过90.88万股， 即不超过公司总股本的1.00%;股东吴波拟通过集中竞价交易方式减持公司股份数量不超过78.58万股， 即不超过公司总股本的0.86%。 ...

毕得医药公告，股东舟山欣曦计划2025年9月29日至2025年12月28日以大宗交易方式减持不超过90.88万 股，占公司总股本1.00%；股东宁波兰旦同期拟以大宗交易方式减持不超过90.88万股，占1.00%；股东 吴波同期拟以集中竞价方式减持不超过78.58万股，占0.86%。三方目前合计持股11.12%，本次减持因资 金需要。 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has shown a strong recovery in its main business, with significant revenue growth and improved profitability metrics. The revenue for the first half of 2025 reached 628 million yuan, a year-on-year increase of 17.91%, while the net profit attributable to the parent company was 73.41 million yuan, up 41.60% year-on-year [4][5] - The company is expected to continue its growth trajectory, with projected revenues of 1.31 billion yuan, 1.58 billion yuan, and 1.92 billion yuan for 2025, 2026, and 2027 respectively, reflecting growth rates of 19.27%, 20.30%, and 21.22% [3][5] Summary by Sections Financial Performance - In 2025, the company achieved a revenue of 1,091.86 million yuan, with a year-on-year growth rate of 30.94% [3] - The net profit attributable to the parent company for 2025 is forecasted to be 145.17 million yuan, representing a growth rate of 23.63% [3] - The gross margin for the first half of 2025 was 44.25%, an increase of 4.74 percentage points year-on-year [5] Business Segments - The drug molecule block business generated 520 million yuan in revenue for the first half of 2025, a growth of 14.35%, while the scientific reagent business saw revenue of 40.73 million yuan, up 87.60% [5] - The company is expanding its product lines and maintaining a stable market share in the drug molecule block sector, contributing to its revenue growth [5] Future Outlook - The company is focusing on new product development and expanding its overseas market presence, with overseas revenue for the first half of 2025 reaching approximately 363 million yuan, a growth of 21.33% [5] - The company is expected to benefit from its competitive advantages and continue to capture market share in the overseas market [5]

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]

Market Overview - On September 4, the medical services sector declined by 4.28%, with Bid Pharma leading the drop [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Notable gainers in the medical services sector included: - Zihua Pharmaceutical (600721) with a closing price of 11.07, up 6.24% [1] - Innovation Medical (002173) with a closing price of 24.99, up 5.31% [1] - Wisdom Pharmaceutical (300149) with a closing price of 13.17, up 4.36% [1] - Major decliners included: - Bid Pharma (688073) with a closing price of 62.65, down 9.44% [2] - WuXi AppTec (603259) with a closing price of 101.94, down 8.06% [2] - Zhaoyan New Drug (603127) with a closing price of 30.92, down 7.48% [2] Capital Flow - The medical services sector experienced a net outflow of 1 billion yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2][3] - Key stocks with significant capital flow included: - Innovation Medical (002173) with a net inflow of 136 million yuan from institutional investors [3] - Wisdom Pharmaceutical (300149) with a net inflow of 79 million yuan from institutional investors [3] - Meinian Health (002044) with a net inflow of 64 million yuan from institutional investors [3]